Fetal bradycardia can be an initial manifestation of LQTS due to rare ankyrin B gene mutations, which can be successfully managed with propranolol.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to consider LQTS with fetal bradycardia; extends phenotypic descriptions but leaves open need for prospective studies.
Long QT syndromes (LQTSs) are inherited disorders of abnormal myocardial repolarization. It is characterized by prolonged QT interval, T wave abnormalities, and tachyarrhythmias such as Torsade de Pointes. Previous literature on congenital LQTS in neonates had reported presentations of cardiac arrhythmias leading to sudden death in the postnatal period. We present here a case of a neonate who presented initially with fetal bradycardia; postnatally developed ventricular tachyarrhythmias which after stabilization showed prolonged QT interval in electrocardiography leading to the diagnosis of LQTS due to a rare mutation in the ankyrin B gene. Acute ventricular tachyarrhythmia was managed with lidocaine and magnesium infusion. We used propranolol to sustain the reduction in QT interval to prevent tachyarrhythmias and Torsades de Pointes and thereby sudden death. On follow-up, the infant showed normal growth and neurodevelopment with QT interval maintained below 500 ms on propranolol prophylaxis. Fetal bradycardia can also be one of the initial manifestations of LQTS due to rare genetic mutations involving the ankyrin B gene.
No takes yet. Share an insight, caveat, or question.
Segaran et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: